XML 16 R5.htm IDEA: XBRL DOCUMENT v3.25.3
CONSOLIDATED STATEMENTS OF CHANGES IN MEZZANINE AND SHAREHOLDERS’ EQUITY - USD ($)
$ in Thousands
Total
PSUs
Class A Common Stock
Class A Common Stock
PSUs
Additional Paid-In Capital
Additional Paid-In Capital
PSUs
Accumulated Other Comprehensive Income (Loss)
Retained Earnings (Accumulated Deficit)
Treasury Stock
Series A preferred stock , beginning balance (in shares) at Dec. 31, 2023 175,000                
Series A preferred stock , beginning balance at Dec. 31, 2023 $ 178,427                
Increase (Decrease) in Temporary Equity [Roll Forward]                  
Net loss attributable to common shareholders of Evolent Health, Inc. $ 8,739                
Series A preferred stock , ending balance (in shares) at Sep. 30, 2024 175,000                
Series A preferred stock , ending balance at Sep. 30, 2024 $ 187,166                
Beginning balance (in shares) at Dec. 31, 2023     115,425,000            
Beginning balance at Dec. 31, 2023 1,067,701   $ 1,154   $ 1,808,121   $ (1,257) $ (719,194) $ (21,123)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Stock-based compensation expense 45,861       45,861        
Exercise of stock options (in shares)     335,000            
Exercise of stock options 3,462   $ 4   3,458        
Restricted stock units vested, net of shares withheld for taxes (in shares)     585,000            
Restricted stock units vested, net of shares withheld for taxes (10,826)   $ 6   (10,832)        
Performance stock units vested, net of shares withheld for taxes (in shares)       205,000          
Performance stock units vested, net of shares withheld for taxes   $ (4,564)   $ 2   $ (4,566)      
Foreign currency translation adjustment (110)           (110)    
Net income (loss) attributable to common shareholders of Evolent Health, Inc. (62,839)       (24,018)     (38,821)  
Ending balance (in shares) at Sep. 30, 2024     116,550,000            
Ending balance at Sep. 30, 2024 $ 1,038,685   $ 1,166   1,818,024   (1,367) (758,015) (21,123)
Series A preferred stock , beginning balance (in shares) at Jun. 30, 2024 175,000                
Series A preferred stock , beginning balance at Jun. 30, 2024 $ 184,206                
Increase (Decrease) in Temporary Equity [Roll Forward]                  
Net loss attributable to common shareholders of Evolent Health, Inc. $ 2,960                
Series A preferred stock , ending balance (in shares) at Sep. 30, 2024 175,000                
Series A preferred stock , ending balance at Sep. 30, 2024 $ 187,166                
Beginning balance (in shares) at Jun. 30, 2024     116,262,000            
Beginning balance at Jun. 30, 2024 1,053,861   $ 1,163   1,810,054   (1,355) (734,878) (21,123)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Stock-based compensation expense 14,416       14,416        
Exercise of stock options (in shares)     234,000            
Exercise of stock options 2,343   $ 3   2,340        
Restricted stock units vested, net of shares withheld for taxes (in shares)     54,000            
Restricted stock units vested, net of shares withheld for taxes (692)       (692)        
Foreign currency translation adjustment (12)           (12)    
Net income (loss) attributable to common shareholders of Evolent Health, Inc. (31,231)       (8,094)     (23,137)  
Ending balance (in shares) at Sep. 30, 2024     116,550,000            
Ending balance at Sep. 30, 2024 $ 1,038,685   $ 1,166   1,818,024   (1,367) (758,015) (21,123)
Series A preferred stock , beginning balance (in shares) at Dec. 31, 2024 175,000                
Series A preferred stock , beginning balance at Dec. 31, 2024 $ 190,173                
Increase (Decrease) in Temporary Equity [Roll Forward]                  
Exchange of Mezzanine equity (in shares) (175,000)                
Exchange of mezzanine equity $ (232,200)                
Net loss attributable to common shareholders of Evolent Health, Inc. $ 42,027                
Series A preferred stock , ending balance (in shares) at Sep. 30, 2025 0                
Series A preferred stock , ending balance at Sep. 30, 2025 $ 0                
Beginning balance (in shares) at Dec. 31, 2024 116,575,773   116,576,000            
Beginning balance at Dec. 31, 2024 $ 1,001,259   $ 1,166   1,803,786   (1,753) (780,817) (21,123)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Stock-based compensation expense 37,343       37,343        
Restricted stock units vested, net of shares withheld for taxes (in shares)     676,000            
Restricted stock units vested, net of shares withheld for taxes (3,346)   $ 7   (3,353)        
Treasury share repurchase, including excise tax (40,308)               (40,308)
Performance stock units vested, net of shares withheld for taxes (in shares)       312,000          
Performance stock units vested, net of shares withheld for taxes   $ (1,822)   $ 3   $ (1,825)      
Foreign currency translation adjustment (623)           (623)    
Net income (loss) attributable to common shareholders of Evolent Health, Inc. $ (150,270)       (44,891)     (105,379)  
Ending balance (in shares) at Sep. 30, 2025 117,564,460   117,564,000            
Ending balance at Sep. 30, 2025 $ 842,233   $ 1,176   1,791,060   (2,376) (886,196) (61,431)
Series A preferred stock , beginning balance (in shares) at Jun. 30, 2025 175,000                
Series A preferred stock , beginning balance at Jun. 30, 2025 $ 228,800                
Increase (Decrease) in Temporary Equity [Roll Forward]                  
Exchange of Mezzanine equity (in shares) (175,000)                
Exchange of mezzanine equity $ (232,200)                
Net loss attributable to common shareholders of Evolent Health, Inc. $ 3,400                
Series A preferred stock , ending balance (in shares) at Sep. 30, 2025 0                
Series A preferred stock , ending balance at Sep. 30, 2025 $ 0                
Beginning balance (in shares) at Jun. 30, 2025     117,473,000            
Beginning balance at Jun. 30, 2025 896,005   $ 1,175   1,782,992   (1,707) (865,332) (21,123)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Stock-based compensation expense 14,682       14,682        
Restricted stock units vested, net of shares withheld for taxes (in shares)     91,000            
Restricted stock units vested, net of shares withheld for taxes (547)   $ 1   (548)        
Treasury share repurchase, including excise tax (40,308)               (40,308)
Foreign currency translation adjustment (669)           (669)    
Net income (loss) attributable to common shareholders of Evolent Health, Inc. $ (26,930)       (6,066)     (20,864)  
Ending balance (in shares) at Sep. 30, 2025 117,564,460   117,564,000            
Ending balance at Sep. 30, 2025 $ 842,233   $ 1,176   $ 1,791,060   $ (2,376) $ (886,196) $ (61,431)